LGP5 LOA
DF-4101 by AbbVie for Solid Tumor: Likelihood of Approval
DF-4101 is under clinical development by AbbVie and currently in Phase I for Solid Tumor. According to GlobalData, Phase I…
RG-6315 by Genentech USA for Inflammation: Likelihood of Approval
RG-6315 is under clinical development by Genentech USA and currently in Phase I for Inflammation. According to GlobalData, Phase I…
GH-21 by HUYA Bioscience International for Non-Small Cell Lung Cancer: Likelihood of Approval
GH-21 is under clinical development by HUYA Bioscience International and currently in Phase I for Non-Small Cell Lung Cancer. According…
HU-6 by Rivus Pharmaceuticals for Hypertriglyceridemia: Likelihood of Approval
HU-6 is under clinical development by Rivus Pharmaceuticals and currently in Phase II for Hypertriglyceridemia. According to GlobalData, Phase II…
Lirafugratinib hydrochloride by Relay Therapeutics for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
Lirafugratinib hydrochloride is under clinical development by Relay Therapeutics and currently in Phase II for Human Epidermal Growth Factor Receptor…